Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Säily M, Uttervall K, Putkonen M, Carlson K, Haukas E, Sankelo M, Szatkowski D, Hansson M, Marttila A, Svensson R, Axelsson P, Lauri B, Mikkola M, Karlsson C, Abelsson J, Ahlstrand E, Sikiö A, Klimkowska M, Matuzeviciene R, Fenstad MH, Ilveskero S, Pelliniemi TT, Nahi H, Silvennoinen R

Open source

DOI: 10.3390/cancers16051024
Published: 2024 Feb 29
Container: Cancers
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers16051024,
  title = {Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.},
  author = {Partanen A and Waage A and Peceliunas V and Schjesvold F and Anttila P and Säily M and Uttervall K and Putkonen M and Carlson K and Haukas E and Sankelo M and Szatkowski D and Hansson M and Marttila A and Svensson R and Axelsson P and Lauri B and Mikkola M and Karlsson C and Abelsson J and Ahlstrand E and Sikiö A and Klimkowska M and Matuzeviciene R and Fenstad MH and Ilveskero S and Pelliniemi TT and Nahi H and Silvennoinen R},
  year = {2024},
  journal = {Cancers},
  doi = {10.3390/cancers16051024},
  url = {https://doi.org/10.3390/cancers16051024}
}

RIS

TY  - JOUR
TI  - Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
AU  - Partanen A
AU  - Waage A
AU  - Peceliunas V
AU  - Schjesvold F
AU  - Anttila P
AU  - Säily M
AU  - Uttervall K
AU  - Putkonen M
AU  - Carlson K
AU  - Haukas E
AU  - Sankelo M
AU  - Szatkowski D
AU  - Hansson M
AU  - Marttila A
AU  - Svensson R
AU  - Axelsson P
AU  - Lauri B
AU  - Mikkola M
AU  - Karlsson C
AU  - Abelsson J
AU  - Ahlstrand E
AU  - Sikiö A
AU  - Klimkowska M
AU  - Matuzeviciene R
AU  - Fenstad MH
AU  - Ilveskero S
AU  - Pelliniemi TT
AU  - Nahi H
AU  - Silvennoinen R
PY  - 2024
JO  - Cancers
DO  - 10.3390/cancers16051024
UR  - https://doi.org/10.3390/cancers16051024
ER  -

APA

A, P., A, W., V, P., F, S., P, A., M, S., K, U., M, P., K, C., E, H., M, S., D, S., M, H., A, M., R, S., P, A., B, L., M, M., C, K., J, A., E, A., A, S., M, K., R, M., MH, F., S, I., TT, P., H, N., & R, S. (2024). Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.. Cancers. https://doi.org/10.3390/cancers16051024

Source records

pubmed · retrieved 2026-11-10T09:24:32.060Z
europe-pmc · retrieved 2026-11-10T09:24:32.065Z